Oxidized Glutathione (NOV-002), Doxorubicin, Cyclophosphamide, and Docetaxel in Treating Women With Newly Diagnosed Stage IIB, or Stage IIIC Breast Cancer
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002) together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women with newly diagnosed stage II or stage III breast cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Drug: Cyclophosphamide Drug: Docetaxel Drug: Doxorubicin hydrochloride Drug: Glutathione disulfide NOV-002 Procedure: conventional surgery |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer |
- Percentage of Participants Achieving Pathologic Complete Response [ Time Frame: 4 years ] [ Designated as safety issue: No ]Pathologic complete response (pCR) is defined according to Hankoop et al [41] as either: the absence of any histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast or the presence of invasive tumor equal to or less than 10mm after preoperative treatment, determined at definitive breast surgery.
- To Define the Safety Profiles of Preoperative Administration of NOV-002 in Combination With Doxorubicin, Cyclophosphamide Followed by Docetaxel. [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
- To Correlate Serum Protein Glutathionylation With Clinical and Pathologic Responses [ Time Frame: 4 years ] [ Designated as safety issue: No ]
| Enrollment: | 41 |
| Study Start Date: | May 2007 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: NOV-002 and Doxorubicin, Cyclophosphamide and Docetaxel | Drug: Cyclophosphamide Drug: Docetaxel Drug: Doxorubicin hydrochloride Drug: Glutathione disulfide NOV-002 Procedure: conventional surgery |
Detailed Description:
OBJECTIVES:
Primary
- The primary objective of this study is to define the rate of pathologic complete response rate (pCR) in the affected breast after the preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with stage IIB-IIIC breast cancer.
Secondary
- Define the safety profiles of preoperative administration of NOV-002 in combination with doxorubicin hydrochloride and cyclophosphamide followed by docetaxel.
- Correlate serum protein glutathionylation with clinical and pathologic responses.
OUTLINE: This is a multicenter study.
Patients receive oxidized glutathione (NOV-002) IV twice on day -1 of course 1 and once on day 1 of courses 2-8. Patients receive NOV-002 subcutaneously once daily on days 2-21 of courses 1-8. Patients also receive chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 of courses 1-4 followed by docetaxel IV on day 1 of courses 5-8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients undergo definitive surgery 3-6 weeks after completion of neoadjuvant therapy.
Blood samples are obtained at baseline and periodically during study to measure serum and plasma protein glutathionlylation. Additional blood samples are collected from some patients for immunological correlative studies.
After completion of study therapy, patients are followed at 30 days.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed infiltrating (i.e., invasive) breast cancer
- Newly diagnosed disease
Clinical stage IIB or IIIC (T2-4, N0 or N1, M0) or (any T, N1-3, M0) disease, as defined by 1 of the following criteria:
- Primary tumor ≥ 2 cm (T2-4)
- Pathologically-proven axillary nodal involvement (N1-3)
- No evidence of metastatic disease except to the ipsilateral axillary lymph nodes
- Disease confirmed by core needle biopsy
- Inflammatory breast cancer (T4) allowed
Clinically palpable disease that is measurable by RECIST AND meets 1 of the following staging criteria:
Primary tumor ≥ 2 cm (T2-4)
- Bilateral synchronic breast cancers allowed, provided 1 of the primary tumors is selected as the target tumor
- Pathologically-proven axillary nodal involvement (N1-3)
- HER-2/neu negative by FISH or 0-2 positive staining by IHC
Hormone-receptor status:
- Estrogen or progesterone receptor-negative or -positive
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- ECOG performance status 0-1
- Life expectancy > 6 months
- ANC ≥ 1,500/mm³
- Platelet count ≥ 1,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST or ALT ≤ 2.5 times ULN
- INR ≤ 1.5
- Creatinine ≤ 2 mg/dL or 177 mmol/L OR calculated creatinine clearance ≥ 50 mL/min
- Cardiac ejection fraction ≥ 50% by baseline MUGA or ECHO
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin or cervical intraepithelial neoplasia
No prior or concurrent clinically significant (i.e., active) cardiac disease, including any of the following:
- New York Heart Association grade II-IV congestive heart failure
- Symptomatic coronary artery disease
- Unstable angina
- Cardiac arrhythmia not well-controlled with medication
- Myocardial infarction within the past 6 months
- No severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer, or bone fracture)
- No known HIV, HBV, or HCV infection
- No known hypersensitivity to any of the components of oxidized glutathione (NOV-002) or to any of the other study drugs
- Patient or caregiver must be able to administer daily subcutaneous injections
PRIOR CONCURRENT THERAPY:
- No prior primary systemic or local treatment for breast cancer, including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapy
- No prior anthracycline- or taxane-based therapy for any other indication
- More than 4 weeks since prior and no other concurrent investigational treatment
- No other concurrent investigational agent
- No other concurrent cytotoxic chemotherapy or hormonal agent
- No other concurrent antineoplastic therapy including, but not limited to, immunotherapy, monoclonal antibody therapy, or targeted agents
No concurrent localized or partial breast radiotherapy
- No other concurrent radiotherapy during the period of study drug administration
- No concurrent growth factors for primary prophylaxis during the first course of treatment
Contacts and Locations| United States, Florida | |
| University of Miami Sylvester Comprehensive Cancer Center - Miami | |
| Miami, Florida, United States, 33136 | |
| United States, South Carolina | |
| Hollings Cancer Center at Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| Study Chair: | Keisuke Shirai, MD | Medical University of South Carolina |
| Principal Investigator: | Alberto Montero, MD | University of Miami Sylvester Comprehensive Cancer Center |
More Information
Additional Information:
Publications:
| Responsible Party: | University of Miami Sylvester Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00499122 History of Changes |
| Other Study ID Numbers: | EPROST-20071167, MUSC-101072, MUSC-HR-17111 |
| Study First Received: | July 10, 2007 |
| Results First Received: | January 18, 2013 |
| Last Updated: | February 20, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Miami Sylvester Comprehensive Cancer Center:
|
stage II breast cancer stage IIIC breast cancer inflammatory breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Docetaxel Doxorubicin Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Pharmacologic Actions Antirheumatic Agents Therapeutic Uses Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic |
ClinicalTrials.gov processed this record on May 22, 2013